All In Biotech

Free tool

FAERS Monitor: Clindesse

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050793 or its brand name (Clindesse, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.

Reports

3,697

Serious

2,334

63% of reports

Hospitalization

1,091

Death reported

269

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective382
  • rash260
  • drug hypersensitivity230
  • off label use230
  • nausea196
  • diarrhoea193
  • pain182
  • fatigue175
  • pruritus174
  • condition aggravated139
  • headache120
  • dyspnoea118
  • pyrexia111
  • product use in unapproved indication109
  • vomiting104

Reports by year received

View as table
YearReports
200418
200548
200658
200714
200825
200948
201086
201175
2012102
2013110
2014107
2015131
2016247
2017216
2018243
2019294
2020214
2021197
2022297
2023306
2024286
2025310
2026264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,462 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal2306.86.01,134
rashSignal2603.43.0446
condition aggravatedSignal1392.62.2137
pruritusSignal1742.62.2169
product use in unapproved indicationSignal1092.52.198
pyrexia1111.81.541
diarrhoea1931.71.557
pain1821.71.552
drug ineffective3821.61.5103
off label use2301.51.339
nausea1961.41.224
fatigue1751.31.111
vomiting1041.31.05
dyspnoea1181.21.03
headache1201.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.